

APSARD 2018 ANNUAL MEETING

ADHD: EVOLVING PERSPECTIVES



PROGRAM BOOK

JANUARY 12-14, 2018

WASHINGTON MARRIOTT

WARDMAN PARK

WASHINGTON, D.C.

JOINTLY SPONSORED BY:

APSARD

The American Professional Society
of ADHD and Related Disorders



APSARD

The American Professional Society
of ADHD and Related Disorders



Dear APSARD Colleagues:

It is my pleasure to welcome you to the 2018 Meeting of the American Professional Society of ADHD and Related Disorders! APSARD is the premier, multidisciplinary organization devoted to the advancement of both the science and clinical practices benefitting individuals with ADHD throughout the lifespan. This year's program is enriched with state of the art plenaries, symposia addressing key issues, posters, and networking opportunities with prominent investigators, clinicians, and colleagues from around the globe who all come to APSARD.

Despite increased awareness of ADHD in all age groups, huge educational gaps remain among primary and specialty care providers, and there is limited access to evidence-based treatments, especially in adults. We need your help in broadening the reach of APSARD and achieving our scientific and educational goals.

Please introduce yourself to any board member or officer if you have suggestions or feedback, and ask about volunteering for APSARD committees. We also hope you will participate in our educational activities throughout the year, refer colleagues for membership, and become more involved through the year.

I know you will enjoy the meeting and interacting with your APSARD colleagues.

With warm regards,

A handwritten signature in black ink that reads "Mark Stein Ph.D." in a cursive, flowing style.

Mark Stein, Ph.D., ABPP
APSARD President



Welcome to the APSARD Annual Meeting

On behalf of the APSARD Annual Meeting Program Committee, we are delighted to welcome you to the 2018 APSARD Annual Meeting.

The conference features nationally and internationally renowned faculty who present recent research findings relevant to clinical practice. If you are new to APSARD and/or the annual meeting, I would like to highlight that APSARD takes great pride in recruiting faculty from the US and abroad who are pre-eminent in the ADHD field, and offering presentations that represent cutting edge science in a manner that is accessible to and informative for clinicians and clinician-researchers. A summary of the schedule is presented below. To me, all sessions are highlights!

- **Friday, January 12**
 - Opening Plenary, *ADHD and Cognition*
 - Welcome Reception
- **Saturday, January 13**
 - Breakfast for Travel Awardees
 - President's Summary
 - Plenary Session: *New Data on Treatment of ADHD and Impairments in Adulthood*
 - Poster Presentations at lunch – Including a Data Blitz Session
 - Symposium Sessions on *ADHD and Technology: The Opportunities and Perils* and *Outside the Pill Bottle: Assessment and Management of Adult ADHD*.
 - Lifetime Achievement Award Plenary: Joseph Sergeant, Ph.D.
 - *Meet the Experts* Sessions (Pharmacotherapy; Psychosocial Intervention)
 - Reception: with Faculty and Attendees
- **Sunday, January 14**
 - APSARD Business Meeting
 - Plenary Sessions, *Genetic and Environmental Factors in ADHD and ADHD As a Brain Disorder: Why is This So Difficult to Establish?*
 - Lunch Discussion Groups on *International Perspectives of ADHD and ADHD in the Prison System*.
 - Symposia Sessions: *New Perspectives on ADHD and Mood Dysregulation and Coaching as an Intervention for Adults with ADHD: What Does the Evidence Tell Us and What Constitute Best Practices?*


Organization

- The meeting is sponsored by the American Society for ADHD and Related Disorders (APSARD).
 - The Program Committee develops program content and invites speakers, evaluates submitted proposals.
- Parthenon Management Group organizes the APSARD Annual Meeting.

The APSARD Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Most importantly, please join us and become a member if you are not already!

Best Regards,



Jeffrey Newcorn, M.D.
Icahn School of Medicine at Mount Sinai


Get Connected...

Download the mobile app for the 2018 APSARD Annual Meeting

Search 'APSARD2018' in the App Store for iPhones
and Google Play Store for Androids today!

The mobile app is a tool that will allow you to browse the Annual Meeting schedule, view abstracts, and plan your agenda for the meeting.

- Tap the Program icon to search the schedule by date and time. Tapping a session will show additional information such as speakers and abstracts.
- Use the Attendees icon to view the APSARD attendee list.
- Tap the Info icon to view helpful documents such as a dining guide with info on area restaurants or a list of presenter disclosures.
- The Facebook and Twitter icons will connect you directly to APSARD social media.
- Logging in to the app will allow you to 'pin' sessions to your schedule that can be uploaded to your phone calendar.



Don't forget to follow us on social media!

@APSARD



APSARD



APSARD WiFi:

WiFi Network: Marriott_CONFERENCE
conference code: apsard2018

TABLE OF CONTENTS

Meeting Space Maps 5

Award Winners and Featured Speakers 7

Acknowledgements..... 23

Meeting Announcements 25

Friday, January 12, 2018..... 31

Saturday, January 13, 2018..... 35

Sunday, January 14, 2018..... 45


Posters 55

Author Index 69


Notes..... 73

MEETING SPACE MAPS

MEZZANINE LEVEL



EXHIBITION LEVEL



NOTES

[illegible]

AWARD WINNERS & FEATURED SPEAKERS

Lifetime Achievement Award



Joseph Sergeant, Ph.D.
Vrije Universiteit

Professor Joseph Sergeant began his research on the attentional problems of hyperactive children in 1975 in Groningen, The Netherlands and from 1985 he was Professor and Chair of Clinical Psychology at the University of Amsterdam. In 1999, he moved to the Vrije Universiteit, Amsterdam to set-up a new department of Clinical Neuropsychology in which he was Professor and chair. In this period, Professor Sergeant set-up with colleagues one of the

largest Adult ADHD neuropsychological projects, which included evaluation with neuropsychological measures the effect of treatment to adult ADHD patients. He is currently emeritus Professor of Clinical Neuropsychology.

In 1987 he founded the European Network on Hyperkinetic Disorders (Eunethydis), which has developed as a key training network for child psychiatrists, neurologists and psychologists. Professor Sergeant handed over the chairmanship of Eunethydis to Professor Tobias Banaschewski January 1st 2015. Under Professor Sergeant's chairmanship, Eunethydis was expanded to take into account the emerging issue of adult ADHD.

Eunethydis has a workgroup: European ADHD Guidelines Group (EAGG) of which Professor Sergeant is chair. EAGG has produced three sets of Guidelines for the treatment of ADHD and a recent meta-analysis of Non-pharmacological interventions in ADHD. An important task for the EAGG in recent years has been to indicate interventions suitable for adult ADHD. Professor Emily Simonoff succeed him as Coordinator of the EAGG January 1st, 2015.

Professor Sergeant has published over 250 articles in scientific journals.

Professor Sergeant was in 2010 knighted by the Queen of The Netherlands and is Officer and Knight in the Order of Oranje Nassau for his contribution to the research and treatment of ADHD individuals.

AWARD WINNERS & FEATURED SPEAKERS

Recipient of the Best Paper in the Journal of Attention Disorders Award

Is Maternal Smoking During Pregnancy a Risk Factor for Cigarette Smoking in Offspring? A Longitudinal Controlled Study of ADHD Children Grown Up

Joseph Biederman, Mary Kate Martelon, K. Yvonne Woodworth, Thomas J. Spencer, and Stephen V. Faraone



Joseph Biederman, M.D.
Massachusetts General Hospital

Dr. Biederman is Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD at the Massachusetts General Hospital, Director of the Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorders at the Massachusetts General Hospital, and Professor of Psychiatry at the Harvard Medical School. Dr. Biederman has been a mentor to more than 15 junior investigators in the field. He is on the editorial board of multiple journals, a reviewer for many Psychiatric journals, and has served as a grant reviewer in the Child Psychopathology and Treatment Review Committee of the NIMH. Dr. Biederman is the author and co-author over 800 scientific articles, 650 scientific abstracts, and 70 book chapters. Dr. Biederman is Board Certified in General and Child Psychiatry.

AWARD WINNERS & FEATURED SPEAKERS

Travel Grant Awardees

Venkat Bhat, M.D.

University of Toronto

Natalie Miller, Ph.D.

University of Maryland - College Park

Mariely Hernandez, M.A.

The City College of New York/
CUNY Graduate Center

Prerona Mukherjee, Ph.D.

MIND Institute, University of
California Davis School of Medicine

Lisa Jacobs, M.B.A., M.D.

Stanford Psychiatry

Luke Norman, Ph.D.

University of Michigan

Traci Kennedy, Ph.D.

University of Pittsburgh

Jameson Patak, B.S.

SUNY Upstate Medical University

AWARD WINNERS & FEATURED SPEAKERS

Featured Speakers



Friday, January 12, 2018 from 5:30 PM – 7:30 PM

ADHD and the Wandering Mind:

A New Perspective on Inattention in ADHD

Phil Asherson, MBBS, MRCPsych, Ph.D.

King's College London

Philip Asherson is Professor of Molecular and Clinical Psychiatry working in the department of Social Genetic and Developmental Psychiatry (SGDP) at the Institute of Psychiatry, Psychology and Neuroscience, King's College London. He completed his Ph.D. on molecular genetic studies of schizophrenia before joining the SGDP in 1996 when he worked with Professor Eric Taylor. He was among the first senior consultants in the UK to specialize in the diagnosis and treatment of ADHD in adults.

Since 1996 he has developed a program of research on clinical, quantitative and molecular genetics of ADHD, with a focus on adults with ADHD. Recent work identified a key role of mood lability in ADHD and he is extending his studies on ADHD to populations in which emotional instability is common. He currently leads a project investigating the effects of methylphenidate on ADHD, aggression and behaviour in young adult offenders with ADHD. He also leads a group investigating clinical, cognitive and neural biomarkers of mind wandering, and their relationship to ADHD and the treatment response to pharmacological and non-pharmacological interventions. He is a member of the guideline development group for the National Institute of Health and Clinical Excellence (NICE) and recently received a Senior Investigator Award for the National Institute of Health Research in the UK.

AWARD WINNERS & FEATURED SPEAKERS



Friday, January 12, 2018 from 5:30 PM – 7:30 PM
So We Find Cognitive Deficits in ADHD:
Big Deal? Where Does This Lead Us?

Trevor Robbins, C.B.E., FRS, Ph.D.
University of Cambridge

Trevor is Professor of Cognitive Neuroscience, being elected to the Chair of Expt. Psychology (and Head of Department until 2017) at the University of Cambridge, from October 2002. He has been based in Cambridge for most of his scientific career, receiving his Ph.D. there in 1975. He is a Fellow of the British Psychological Society (1990), the Academy of Medical Sciences (2000), and the Royal Society (2005) the most prestigious science society in the U.K. He has published about 800 full papers, with an H index of about 173. He has co-edited eight books, most recently Translational Neuropsychopharmacology (Springer, 2016)). He edits Psychopharmacology (since 1980) and Current Opinion in the Behavioral Sciences and is an editorial advisor for Science.

Trevor directs the 'Behavioural and Clinical Neuroscience Institute' (BCNI) (founded in 2005 with funding from the MRC and Wellcome Trust) the mission of which is to enhance translation from basic to clinical neuroscience with particular reference to impulsive-compulsive disorders including drug addiction. His interest in translation began with his co-invention in 1987 of the CANTAB computerized neuropsychological battery, which is currently used in over 700 institutes and clinical centers world-wide.

He received the Distinguished Scientific Contribution Award for 2011 from the American Psychological Association. He was made a CBE in the New Year's Honours list of the U.K. in 2012 "for services to medical research". In 2014 he shared the 'Brain Prize' of the Grete Lundbeck European Brain Research Foundation, the most valuable in neuroscience, for his work on human mental disorders. In 2015 he received the "Lifetime Achievement Award" of the British Association for Psychopharmacology'. In 2016, he received the Robert Sommer Award for research into schizophrenia. In 2017 received the Gold Medal of the Society for Biological Psychiatry (USA) work on cortico-striatal systems and their modulation, and, most recently, the Patricia Goldman-Rakic Award in Cognitive Neuroscience.

AWARD WINNERS & FEATURED SPEAKERS



Friday, January 12, 2018 from 5:30 PM – 7:30 PM
Is ADHD a Disorder of Cognition?

Anthony Grace, Ph.D.
University of Pittsburgh

Dr. Anthony A. Grace is a Distinguished Professor of Neuroscience and a Professor of Psychiatry and Psychology at the University of Pittsburgh in Pittsburgh, PA. He received his Ph.D. from Yale University School of Medicine with Dr. Benjamin S. Bunney and had postdoctoral training with Dr. Rodolfo Llinas in the Department of Physiology and Biophysics at New York University School of Medicine. Dr. Grace has been involved in translational research related to the dopamine system for over 30 years. His early work pioneered the mode of action of antipsychotic drugs, and the identification and characterization of dopamine-containing neurons, and was the first to provide a means to quantify their activity state and pattern in a way that is the standard in the literature. His current work involves novel treatments for schizophrenia and its prevention, the role of dopamine in anhedonia and affective disorders, and the mode of action of ketamine and novel antidepressant drugs. Dr. Grace has received several awards for his research, including the William K. Warren Award for Excellence in Schizophrenia Research, the Paul Janssen Schizophrenia Research Award and the Lilly Basic Scientist Award from the International College of Neuropsychopharmacology, the Efron Award and the Axelrod Award from the American College of Neuropsychopharmacology, the Gold Medal award from the Society of Biological Psychiatry, the Outstanding Basic Research award from the Schizophrenia International Research Society, as well as a NIMH MERIT award, a Distinguished Investigator award from the National Alliance for Research in Schizophrenia and Depression, the Judith Silver Memorial Investigator Award from the National Alliance for the Mentally Ill, a Fellow of the American Association for the Advancement of Science, and appointment as a Distinguished Professor of Neuroscience at the University of Pittsburgh. He is also a past member of the governing council of the American College of Neuropsychopharmacology and the Schizophrenia International Research Society and is on the editorial board for numerous leading journals in the field. Tony has made a substantial impact on the field, publishing more than 300 articles (H index 92) spanning basic and clinical research, and has been cited nearly 30,000 times. Tony is one of a handful of individuals that not only performs important basic research, but can to integrate this work into testable models relevant to the human condition.

AWARD WINNERS & FEATURED SPEAKERS



Saturday, January 13, 2018 from 9:00 AM – 11:00 AM
ADHD Treatment and Risk for Substance Abuse Disorders

Tim Wilens, M.D.
Massachusetts General Hospital

Dr. Wilens is Chief of Child and Adolescent Psychiatry, and (Co) Director of the Center for Addiction Medicine at the Massachusetts General Hospital. Dr. Wilens specializes in the diagnosis and treatment of ADHD, substance use disorders, and bipolar disorder. Widely published, Dr. Wilens has more than 350 original articles, reviews, chapters, books and editorials to his credit. Dr. Wilens is a consultant to the National Football League, Major/Minor League Baseball, Bay Cove Human Services and Phoenix House and is consistently named one of the Best Doctors in Boston and in America for psychiatry.

AWARD WINNERS & FEATURED SPEAKERS



Saturday, January 13, 2018 from 9:00 AM – 11:00 AM
Health Outcomes of ADHD: Do They Adversely Impact Life Expectancy?

Russell Barkley, Ph.D.

Virginia Commonwealth University Medical Center

Russell A. Barkley, Ph.D., is a Clinical Professor of Psychiatry at the Virginia Treatment Center for Children and Virginia Commonwealth University Medical Center, Richmond, VA. He is a Diplomate (board certified) in three specialties, Clinical Psychology (ABPP), Clinical Child and Adolescent Psychology, and Clinical Neuropsychology (ABCN, ABPP). Dr. Barkley is a clinical scientist, educator, and practitioner who has published 23 books, rating scales, and clinical manuals numbering 41 editions. He has also published more than 270 scientific articles and book chapters related to the nature, assessment, and treatment of ADHD and related disorders. He is the founder and Editor of the bimonthly clinical newsletter, The ADHD Report, now in its 25th year of publication. Dr. Barkley has presented more than 800 invited addresses internationally and appeared on nationally televised programs such as 60 Minutes, the Today Show, Good Morning America, CBS Sunday Morning, CNN, and many other programs on behalf of those with ADHD. He has received awards from the American Psychological Association, American Academy of Pediatrics, American Board of Professional Psychology, Association for the Advancement of Applied and Preventive Psychology, American Professional Society for ADHD and Related Disorders, New England Educational Institute, the Wisconsin Psychological Association, and Children and Adults with ADHD (CHADD) for his career accomplishments, contributions to research in ADHD, to clinical practice, and for the dissemination of science. His websites are www.russellbarkley.org and ADHDLectures.com

AWARD WINNERS & FEATURED SPEAKERS



Saturday, January 13, 2018 from 9:00 AM – 11:00 AM

**The Risks and Benefits of ADHD Medication:
A Pharmacoepidemiologic Perspective**

Brian D'Onofrio, Ph.D.

Indiana University

Brian D'Onofrio is a Professor and the Director of Clinical Training in the Department of Psychological and Brain Sciences at Indiana University in Bloomington, IN. He received his doctorate from the University of Virginia in 2005 after completing his clinical internship at Children's Hospital Boston/Harvard Medical School. His research focuses on the causes and treatment of psychological disorders using large-scale datasets and advanced epidemiologic methods. He has worked with several international research teams and has received funding from the NIMH, NICHD, NIDA, NSF, American Foundation for Suicide Prevention, NARSAD, Indiana Clinical and Translational Sciences Institute, Indiana University, and international funding agencies.

AWARD WINNERS & FEATURED SPEAKERS



Sunday, January 14, 2018 from 9:00 AM – 10:30 AM
ADHD: Progress in Identifying Genetic and Environmental Risk Factors

Anita Thapar, FRC.Psych, F.Med.Sci.
Cardiff University

Anita heads the academic Child & Adolescent Psychiatry section at the Division of Psychological Medicine and Clinical Neurosciences, Cardiff University and also directs the developmental disorders group within the MRC Centre for Neuropsychiatric Genetics and Genomics.

Her research focuses on the origins, development and complications of child neurodevelopmental disorders focusing mainly on ADHD. Currently funded research investigations focus on the natural history of ADHD and Autism into adult life, preterm birth and its genetic links with neurodevelopmental disorders and the contribution of genetic and early life exposures to ADHD and ASD trajectories.

Anita trained in Medicine, Psychiatry and Child and Adolescent Psychiatry in Cardiff and South Wales. She was Senior Lecturer in Child and Adolescent Psychiatry at the University of Manchester between 1996 and 1999. She then became the first Professor in Child and Adolescent Psychiatry in Wales in 1999 and developed research, teaching and a specialist clinical service (an NHS tertiary service for child neurodevelopmental disorders and “transition” ADHD clinic for 15 to 25-year olds).

In 2015, she served as lead editor (together with Dr. Daniel S. Pine, NIMH) of the authoritative international textbook Rutter’s Textbook of Child and Adolescent Psychiatry. Anita was awarded a CBE for services to Child and Adolescent Psychiatry in 2017, the President’s Medal from the Royal College of Psychiatrists in 2015 for contributions to policy, public knowledge, education and meeting population and patient care needs and the Ruane Prize 2015 from the Brain and Behavior Research Foundation, USA for outstanding Child & Adolescent Psychiatric research.

She is married to a GP and has two sons.

<https://www.cardiff.ac.uk/people/view/126769-thapar-anita>

AWARD WINNERS & FEATURED SPEAKERS



Sunday, January 14, 2018 from 9:00 AM – 10:30 AM
Beyond Heritability – Have Studies of the Effects of Institutional Deprivation Changed How We Conceptualise ADHD?

**Edmund Sonuga-Barke, M.Sc., Ph.D.,
F.Med.Sci.**

King's College London

Edmund Sonuga-Barke is currently Professor of Developmental Psychology, Psychiatry and Neuroscience working in the Department of Child and Adolescent Psychiatry at the Institute of Psychology, Psychiatry and Neuroscience, King's College London. He also holds Visiting Chairs at Ghent University, Aarhus University and the University of Sussex. He is Editor in Chief of the Journal of Child Psychology and Psychiatry.

His work integrates Developmental Psychopathology and Neuroscience perspectives to employing basic developmental science approaches to study the pathogenesis of neuro-developmental and mental health conditions; their underlying genetic and environmental risks, mediating brain mechanisms and developmental outcomes. He has a particular interest in ADHD and related disorders.

In 2016, Prof Sonuga-Barke was elected a Fellow of the Academy of Medical Sciences.

AWARD WINNERS & FEATURED SPEAKERS



Sunday, January 14, 2018 from 11:00 AM – 12:30 PM
ADHD as a Brain Disorder: Why Is This So
Difficult to Establish?

Stephen Faraone, Ph.D.
SUNY Upstate Medical University

Stephen Faraone, Ph.D., is a Distinguished Professor in the Departments of Psychiatry and Neuroscience & Physiology at SUNY Upstate Medical University and Director of Medical Genetics Research for the University. He is also Senior Scientific Advisor to the Research Program Pediatric Psychopharmacology at the Massachusetts General Hospital and a lecturer at Harvard Medical School. Prof. Faraone is Chair of the ADHD Subgroup of the Psychiatric Genomics Consortium (PGC) and is a founding member of the PGC Coordinating Committee. He is also Editor of Neuropsychiatric Genetics. An author on over 800 journal articles, editorials, chapters and books, he was the eighth highest producer of High Impact Papers in Psychiatry from 1990 to 1999 as determined by the Institute for Scientific Information (ISI, Science, 2000, Vol 288, pg 959). In 2005, ISI determined him to be the second highest cited author in the area of Attention Deficit Hyperactivity Disorder (<http://www.esi-topics.com/add/interviews/StephenFaraone.html>) and in 2013 he was the third most highly cited researcher in psychiatry and psychology (<http://academic.research.microsoft.com/>). His lifetime H-Index as of Feb 2016 was 171.

AWARD WINNERS & FEATURED SPEAKERS



Sunday, January 14, 2018 from 11:00 AM – 12:30 PM
ADHD as a Brain Disorder: Why Is This So
Difficult to Establish?

Barbara Franke, Prof. Dr.
Radboud Universiteit

Barbara Franke is a Professor of Molecular Psychiatry at the Radboud University in Nijmegen, The Netherlands, based at the departments of Human Genetics and Psychiatry of the Radboud University Medical Center. She is also Principal Investigator at the Donders Institute for Brain, Cognition and Behaviour in Nijmegen. At Radboudumc, she is the Chief of the Division of Genome Research and Leader of the Radboud Research Theme Neurodevelopmental Disorders.

As a biologist and geneticist, her research is focused on understanding the biology of (neurodevelopmental) psychiatric disorders, with a particular focus on ADHD. In addition to performing gene-finding studies, she uses bioinformatics, neuroimaging genetics, and small animal models to map biological pathways leading from gene to disease. She is the founder of the International Multicenter persistent ADHD Collaboration (IMpACT) and the coordinator of several international consortia funded by the European Union, including the Aggressotype and MiND projects on ADHD comorbidity with aggression and autism. She also is a founding member and member of the central support group of the ENIGMA consortium on neuroimaging and genetics in health and disease and leads the ADHD Working Group within ENIGMA. Barbara Franke has co-authored over 350 papers, her current H-factor is 70. She has received several prizes and awards, including Aspasia and Vici awards from the Netherlands Organization for Scientific Research (NWO) and the Radboud Hermesdorf International Prize 2013. She is an elected member of the Royal Netherlands Academy of Arts and Sciences, the Royal Holland Society of Sciences and Humanities, and Academia Europaea.

AWARD WINNERS & FEATURED SPEAKERS



Sunday, January 14, 2018 from 11:00 AM – 12:30 PM
ADHD as a Brain Disorder: Why Is This So
Difficult to Establish?

John Gabrieli, Ph.D.

Massachusetts Institute of Technology

John Gabrieli is the director of the Athinoula A. Martinos Imaging Center at the McGovern Institute. He is an Investigator at the Institute, with faculty appointments in the Department of Brain and Cognitive Sciences and the Institute for Medical Engineering & Science, where he holds the Grover Hermann Professorship. He also has appointments in the Department of Psychiatry at Massachusetts General Hospital and the Harvard Graduate School of Education, and is the director of the MIT Integrated Learning Initiative. Prior to joining MIT in 2005, he spent 14 years at Stanford University in the Department of Psychology and Neurosciences Program. He received a Ph.D. in Behavioral Neuroscience in the MIT Department of Brain and Cognitive Sciences and a B.A. in English from Yale University. In 2016 he was elected to the American Academy of Arts and Sciences.

AWARD WINNERS & FEATURED SPEAKERS



Sunday, January 14, 2018 from 11:00 AM – 12:30 PM
ADHD as a Brain Disorder: Why Is This So
Difficult to Establish?

Jay Giedd, M.D.

University of California San Diego

Jay N. Giedd, M.D. is a professor in the Department of Psychiatry at the University of California, San Diego, and Director of the Division of Child and Adolescent Psychiatry at UCSD and Rady Children's Hospital-San Diego. In addition, he is an adjunct professor at Johns Hopkins School of Public Health in the Department of Family and Reproductive Medicine and at Fukui University, Japan. Over the past 26 years Dr. Giedd has combined brain imaging, genetics, and behavioral analysis to explore the path, mechanisms, and influences of brain development in health and illness. As one of the most highly cited child psychiatrist of his generation, his over 300 scientific publications have had a transformative impact on medicine, psychology, education, judicial, and public policy. Throughout his career he has maintained a strong personal, clinical, and research interest in ADHD. A member of the CHADD Hall of Fame, he is amongst a group of researchers who uses genetics and neuroimaging to help characterize the neurobiology of ADHD with the goal of seeking to improve interventions and reduce public misconceptions about the illness. His recent work has focused on how new insights from pediatric neuroscience can be used to optimize the environment for healthy brain development, particularly regarding education and the use of digital technologies that have transformed the way youth learn, play, and interact with each other. For his outreach to students of all ages and frequent talks to parents, teachers, mental health workers, legislators, and the general public, Dr. Giedd was honored as co-recipient of the 2012 Society for Neuroscience's Science Educator Award.

NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

ACKNOWLEDGEMENTS

Program Committee Members

Jeffrey Newcorn, M.D.
Program Committee Chair
Icahn School of Medicine at Mount
Sinai

Lenard Adler, M.D.
New York University School of
Medicine

Joseph Biederman, M.D.
Massachusetts General Hospital

Lisa Chiu, N.P.
Seattle Children's Hospital

Frances Levin, M.D.
Columbia University Medical
Center

Scott Kollins, Ph.D.
Program Committee Co-Chair
Duke University

Kathleen Nadeau, Ph.D.
Chesapeake ADHD Center of
Maryland

Luis Rohde, M.D.
Federal University of Rio Grande
Do Sul

Steven Pliszka, M.D.
University of Texas San Antonio

Russell Schachar, M.D.
University of Toronto

APSARD Officers and Board

Mark Stein, Ph.D., ABPP
President
Seattle Children's Hospital

Joseph Biederman, M.D.
President Elect
Massachusetts General Hospital

Anthony Rostain, M.D., MA
Past President
University of Pennsylvania

Betsy Busch, M.D., FAAP
Secretary
Tufts University School of Medicine

Vatsal Thakkar, M.D.
Treasurer
New York University School of
Medicine

ACKNOWLEDGEMENTS

APSARD Officers and Board (continued)

Thomas Brown, Ph.D.
Keck School of Medicine of
University of Southern California

Greg Mattingly, M.D.
Washington University School of
Medicine

Stephen Faraone, Ph.D.
SUNY Upstate Medical University

Jeffrey Newcorn, M.D.
Icahn School of Medicine at Mount
Sinai

Robert Findling, M.D., MBA
Johns Hopkins School of Medicine

Andrew Nierenberg, M.D.
Massachusetts General Hospital

Tanya Froehlich, M.D.
Cincinnati Children's Hospital
Medical Center

Russell Ramsay, Ph.D.
University of Pennsylvania

Sam Goldstein, Ph.D.
Journal of Attention Disorders

Mary Solanto, Ph.D.
New York University School of
Medicine

David Goodman, M.D.
Johns Hopkins School of Medicine

Thomas Spencer, M.D.
Harvard Medical School

John Heiligenstein, M.D.
Pharmaceutical Industry

Craig Surman, M.D.
Massachusetts General Hospital

J.J. Sandra Kooij, M.D., Ph.D.
PsyQ, Psycho-Medical Programs,
The Hague

Roberta Waite, Ed.D
Drexel University

Keith McBurnett, Ph.D.
University of California, San
Francisco

Margaret Weiss, M.D., Ph.D.
University of British Columbia
Children and Women's Health
Centre

Iris Manor, M.D.
Tel Aviv University

MEETING ANNOUNCEMENTS

Meeting Services

Registration Desk Hours:

Friday, January 12 2:00 PM – 7:00 PM

Saturday, January 13 7:00 AM – 6:00 PM

Sunday, January 14 7:30 AM – 4:00 PM

*The registration/meeting information desk is located in the Thurgood Marshall Foyer on the Mezzanine Level.

The APSARD Speaker Ready Room is open on the below dates and times for presenters to upload slides. The meeting organizers ask that all speakers upload their slides 4 hours prior to their scheduled presentation time.

The Speaker Ready Room is located in the Taft Meeting Room on the Mezzanine Level.

Friday, January 12 1:00 PM – 6:00 PM

Saturday, January 13 7:00 AM – 5:30 PM

Sunday, January 14 7:00 AM – 3:00 PM

Americans with Disabilities Act - It is the policy of APSARD not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3083 or send an email to info@apsard.org.

APSARD Mobile App- The APSARD mobile app is now available in the app store for iPhones and in Google Play for Androids. Search APSARD2018 and download today! View the latest schedule, attendee list and abstracts!

MEETING ANNOUNCEMENTS

Continuing Education Credits

Continuing Education Credits are available for physicians, psychologists and nurses. Applications for credit must be completed online with the meeting evaluation. The evaluation may be completed after the conference at www.APSARD.org/meeting/program. ***Evaluations for continuing education credit must be submitted no later than February 9, 2018.***

Disclosures

Disclosures are available for all APSARD Annual Meeting presenters online at www.APSARD.org/meeting/program. It is the policy of the APSARD to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Accreditation Statements

This meeting is jointly sponsored by the American Professional Society of ADHD and Related Disorders and AMEDCO.



Continuing Education Credit Information:

Satisfactory completion

Participants must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. NOTE: If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

MEETING ANNOUNCEMENTS

Physicians

Accreditation Statement – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and American Professional Society of ADHD & Related. Amedco is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement – Amedco designates this live activity for a maximum of 14.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This course is co-provided by Amedco and American Professional Society of ADHD & Related. Maximum of 14.00 contact hours.

Psychologists

This course is co-sponsored by Amedco and American Professional Society of ADHD & Related. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and its content. 14.00 hours.

Professional Counselors in these 37 states can submit APA = AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KY, KS, ME, MO, NC, ND, NH, NE, NJ, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WI, WY

AL / Counselors: Activities not providing NBCC approval may be approved by the Board for individual licensees upon receipt of acceptable documentation prior to the activity. Please send course details to your licensing board for approval BEFORE the event. No approvals afterward by the board.

MFT's in these 31 states can submit APA = AK, AR, AZ, CA, CO, CT, DE, FL, IA, ID, IN, KS, ME, MO, NE, NC, NH, NM, NJ, NV, OK, OR, PA, SC, SD, TN, TX, UT, VA, WI, WY

Addictions Professionals in these 25 states can submit APA = AK, AR, CO, CT, DE, GA, IA, IN, KS, LA, MO, MT, NE, NM, NC, ND, NJ, NV, NY (outstate held), OK, OR, SC, UT, WA, WI, WY

Social Workers in these 22 states can submit APA = AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY

MEETING ANNOUNCEMENTS

Social Workers

Amedco, #1346, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, through the Approved Continuing Education (ACE) program. Amedco maintains responsibility for the program. ASWB Approval Period: 6/24/2016 to 6/24/2019. Social workers should contact their regulatory board to determine course approval for continuing education credits.

Social workers participating in this course may receive up to 14.00 clinical continuing education clock hours.

Professional Counselors in these 30 states can submit ASWB = AK, AR, AZ, CA, CO, CT, DC, FL, GA, IA, ID, IL, IN, KS, ME, MO, ND, NE, NM, NH, NV, OK, PA, TN, TX, UT, VA, WI, WY

AL / Counselors: Activities not providing NBCC approval may be approved by the Board for individual licensees upon receipt of acceptable documentation prior to the activity. Please send course details to your licensing board for approval BEFORE the event. No approvals afterward by the board.

MFT's in these 25 states can submit ASWB = AK, AR, AZ, CA, CO, FL, IA, ID, IN, KS, ME, MO, NC, NE, NH, NM, NV, OK, PA, TN, TX, UT, VA, WI, WY

Addictions Professionals in these 21 states can submit ASWB = AK, CA, CO, CT, GA, IA, IN, KS, LA, MO, MT, ND, NM, NV, OK, OR, SC, WA, WI, WV, WY

All participants who request continuing education credits by February 9, 2018, should expect to receive their statement of credits via email in March.

The Meeting Evaluation Survey will be available at www.APSARD.org. We encourage all registrants to complete the evaluation. Attendees requesting CME, MOC, or CE credits must complete the survey in order to obtain credits. Your candid input on the 2018 meeting is appreciated as we strive to improve the meeting each year.

MEETING ANNOUNCEMENTS

APSARD would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting:

Pfizer
Supernus Pharmaceuticals

APSARD Society Support

APSARD would like to thank the following sponsors for their generous donations to the society:

Platinum Sponsor:



Bronze Sponsors:



Exhibitors

Please visit the exhibitors in the Exhibit Hall C Foyer during the meeting.

- Arbor Pharmaceuticals
- CHADD
- Ironshore Pharmaceuticals
- NLS-1 Pharma Inc.
- Qbtech
- Reimbursify
- Rhodes Pharmaceuticals
- Shire Pharmaceuticals
- Tris Pharmaceuticals
- The TOVA Company
- Vaya Pharmaceuticals

Please note, due to print deadlines there may be additional exhibitors or supporters not listed in this program.

NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

SCHEDULE AT A GLANCE

FRIDAY, JANUARY 12, 2018

2:00 PM – 7:00 PM	Registration Open Thurgood Marshall Foyer – Mezzanine Level
5:30 PM – 7:30 PM	Welcome and Opening Plenary Session: <i>ADHD and Cognition</i> Thurgood Marshall Ballroom
7:30 PM – 9:00 PM	Reception and Poster Viewing Exhibit Hall C

NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

FULL SCHEDULE

FRIDAY, JANUARY 12, 2018

1:00 PM – 3:00 PM **APSARD Board Meeting (By Invitation)**
Hoover

2:00 PM – 7:00 PM **APSARD Registration**
Thurgood Marshall Foyer

3:30 PM – 5:00 PM **APSARD Membership Committee
(By Invitation)**
Coolidge

3:30 PM – 5:00 PM **APSARD Social Media and Education
Committee Meeting (By Invitation)**
Harding

5:30 PM – 7:30 PM **Welcome and Opening Plenary Session:
ADHD and Cognition**
Thurgood Marshall Ballroom

Chair: Philip Asherson, Kings College London

ADHD and the Wandering Mind: A New Perspective on Inattention in ADHD

Philip Asherson, Kings College London

The Translational Neuropsychopharmacology of ADHD

Trevor Robbins, University of Cambridge

Tonic-Phasic Dopamine Regulation of Limbic System Integration in the Pathophysiology and Treatment of ADHD

Anthony Grace, University of Pittsburgh

Overall Abstract: This session will outline different models of cognitive and neural processes that underlie the symptoms, impairments and treatment response to medication in ADHD. The three speakers focus on different models of ADHD. First, Professor Asherson discusses the potential role of mind wandering as a core feature of the ADHD mental state, linked to aberrant regulation of default mode and salience network activity. This model is closely aligned to the default mode interference model and highlights early sensory deficits in addition to difficulties with executive

FULL SCHEDULE

control. Second, Professor Robbins discusses the role of noradrenaline and dopamine in sustained attention, working memory and impulse control; highlighting the lack of detailed information on the mechanisms by which changes in catecholamine functioning lead to the changes in cortico-striatal networks seen in ADHD. Finally, Professor Grace discusses in detail the paradoxical effects of stimulants in ADHD and controls. Dopamine system activity is characterized into two categories: the slowly changing, homeostatic low level tonic transmission, and the rapid, high-amplitude phasic transmission. These two types of transmission furthermore interact to modulate dopamine system responsivity and reduce symptoms such as inattention and hyperactivity when used to treat ADHD. Taken together, these talks provide state a state of the art update on contemporary models of ADHD and the treatment response to medication, highlighting the heterogeneity of the disorder, and areas for further research.

Learning Objectives:

- To understand the role of excessive spontaneous mind wandering in ADHD.
- To understand the role of executive control dysfunctions in ADHD.
- To understand the role of phasic and tonic dopamine neurotransmission and their relationship to ADHD and the treatment response to medication.
- To learn about key models of ADHD and the heterogeneity of processes underlying ADHD symptoms and the treatment response to medication.

7:30 PM – 9:00 PM

Reception and Poster Viewing

Exhibit Hall C

***See pages 55 through 67 for a complete listing of posters.

SCHEDULE AT A GLANCE

SATURDAY, JANUARY 13, 2018

7:00 AM – 6:00 PM	Registration Open Thurgood Marshall Foyer – Mezzanine Level				
7:00 AM – 8:00 AM	APSARD Travel Fellow Breakfast (By Invitation) Coolidge				
7:30 AM – 8:30 AM	Morning Break Atrium Foyer outside of Exhibit Hall C				
8:00 AM – 8:45 AM	President's Summary: <i>State of APSARD</i> Thurgood Marshall Ballroom				
9:00 AM – 11:00 AM	Plenary Session: <i>New Data on Treatment of ADHD and Impairments in Adulthood</i> Thurgood Marshall Ballroom				
11:00 AM – 11:30 AM	Coffee Break Atrium Foyer outside of Exhibit Hall C				
11:30 AM – 12:30 PM	Lifetime Achievement Plenary Session: <i>Brain States and Functions in Transitioning ADHD</i>, Joseph Sergeant, Ph.D. Thurgood Marshall Ballroom				
12:30 PM – 1:30 PM	Data Blitz Session Lincoln 3-4				
12:30 PM – 2:30 PM	Poster Session with Lunch Exhibit Hall C				
2:30 PM – 4:30 PM	Symposia Sessions				
<table border="1"> <tr> <td><i>ADHD and Technology: The Opportunities and Perils</i></td><td><i>Outside the Pill Bottle: Assessment and Management of Adult ADHD</i></td></tr> <tr> <td>Thurgood Marshall Ballroom</td><td>Lincoln 3-4</td></tr> </table>		<i>ADHD and Technology: The Opportunities and Perils</i>	<i>Outside the Pill Bottle: Assessment and Management of Adult ADHD</i>	Thurgood Marshall Ballroom	Lincoln 3-4
<i>ADHD and Technology: The Opportunities and Perils</i>	<i>Outside the Pill Bottle: Assessment and Management of Adult ADHD</i>				
Thurgood Marshall Ballroom	Lincoln 3-4				
4:30 PM – 5:00 PM	Coffee Break Atrium Foyer outside of Exhibit Hall C				

SCHEDULE AT A GLANCE

5:00 PM – 6:15 PM	Ask the Experts Sessions: Pharmacotherapy Coolidge
5:00 PM – 6:15 PM	Ask the Experts Sessions: Psychosocial and Risk Prevention Hoover
6:15 PM – 7:30 PM	Reception and Poster Viewing Exhibit Hall C

FULL SCHEDULE

SATURDAY, JANUARY 13, 2018

7:00 AM – 6:00 PM	APSARD Registration Thurgood Marshall Foyer
7:00 AM – 8:00 AM	APSARD Travel Fellow Breakfast (By Invitation) Coolidge
7:30 AM – 8:30 AM	Morning Break Exhibit Hall C Foyer
8:00 AM – 8:45 AM	President's Summary: <i>State of APSARD</i> Thurgood Marshall Ballroom Mark Stein, University of Washington
9:00 AM – 11:00 AM	Plenary Session: <i>New Data on Treatment of ADHD and Impairments in Adulthood</i> Thurgood Marshall Ballroom

Chair: Frances Levin, Columbia University Medical Center

What Effect Does ADHD Medication Treatment Have on the Later Risk for Substance Use Disorders?

Timothy Wilens, Massachusetts General Hospital

Health Outcomes of ADHD: Do They Adversely Impact Life Expectancy?

Russell Barkley, Virginia Commonwealth University Medical Center

The Risks and Benefits of ADHD Medication: A Pharmacoepidemiologic Perspective

Brian D'Onofrio, Indiana University

Overall Abstract: There is overwhelming evidence that ADHD increases the risk of substance use disorders (SUDs), as well other medical and psychiatric disorders. While early studies found that pharmacologic treatment of ADHD in childhood reduced the risk of adolescent substance use disorder, this was less evident as adolescents matured into adulthood. Dr. Wilens will present recent data, based on large survey, registry and clinical studies that have found that early childhood pharmacologic treatment prescribed for longer duration reduces the risk of substance use disorder in adolescence

FULL SCHEDULE

and early adulthood. Similar to SUDs, other harmful behaviors such as accidental injuries, eating pathology and tobacco use is associated with having ADHD. Based on data collected from the Milwaukee longitudinal study, Dr. Barkley will discuss how these adverse outcomes might impact on life expectancy. Finally, Dr. D'Onofrio will discuss how analyses of large-scale health insurance claims datasets in the US and national registry data in Sweden can elucidate how various adverse outcomes, such as serious substance use problems, accidents, other psychiatric comorbidities are associated with periods of dispensed/non-dispensed ADHD medications within individual comparisons. The implications of these data, both in terms of prevention and mitigating harmful outcomes into adulthood will be discussed.

Learning Objectives:

- To learn what factors are associated with reduced risk of developing SUDs among those with ADHD.
- To become knowledgeable of the adverse health outcome associated with ADHD and the potential impact on longevity.
- To become familiar with the various large scale datasets, survey data, and clinical longitudinal studies that may elucidate how the risk of SUD, and other health outcomes, may be mitigated by early intervention and ongoing treatment.

11:00 AM – 11:30 AM **Coffee Break**
Exhibit Hall C Foyer

11:30 AM – 12:30 PM **Lifetime Achievement Plenary Session: *Brain States and Functions in Transitioning ADHD***
Thurgood Marshall Ballroom

Chair: Mark Stein, University of Washington

Brain States and Functions in Transitioning ADHD

Joseph Sergeant, Vrije Universiteit Amsterdam

Overall Abstract: The 2018 Lifetime Achievement Award is presented to Professor Joseph A. Sergeant. This award recognizes Professor Sergeant's longstanding dedication to the ADHD field and his substantial achievements in building the science of ADHD and its treatment. Professor Sergeant was the developer of the Cognitive Energetic Model of ADHD, and has subsequently gone on to study various aspects linking clinical and

FULL SCHEDULE

neuropsychological mechanisms with brain function. He is also the founder of the European Network for Hyperkinetic Disorders (EUNETHYDIS), which has been a highly successful model of collaboration for collaborative research, training, and the development and dissemination of clinical guidelines. We are especially honored to have Professor Sergeant with us because of the impact Eunethydis has had on the recent growth and development of APSARD in the US. Professor Sergeant's talk will examine the very timely issue of ADHD as a brain-based neuropsychiatric disorder.

Learning Objectives:

- To highlight the study of brain behavior relationships in ADHD from childhood to adulthood.
- To provide an overview of how advances in neuroscience have led to increased understanding of ADHD throughout the world.

12:30 PM – 1:30 PM **Data Blitz Session**
Lincoln 3-4

Chair: Joseph Biederman, Massachusetts General Hospital

12:30 PM – 12:35 PM Introduction

12:35 PM – 12:39 PM **Does Exposure to Parental Substance Use Disorders Increase Offspring Risk for a Substance Use Disorder? A Longitudinal Follow-Up Study Into Young Adulthood**
Amy Yule, Harvard Medical School/Massachusetts General Hospital

12:40 PM – 12:44 PM **Do Subsyndromal Manifestations of MDD in Children at Genetic Risk for MDD Predict the Development of Major Depression? A Five-Year Longitudinal Controlled Study**
Joseph Biederman, Massachusetts General Hospital

12:45 PM – 12:49 PM **Response Time Adjustment in the Stop Signal Task Serve as a Marker of Reinforcement Learning: Development in Typically Developing and ADHD Children and Adolescents**
Russell Schachar, University of Toronto

FULL SCHEDULE

- 12:50 PM – 12:54 PM **Reverse Microdialysis Studies of d-, l-, & d,l-Amphetamine-Evoked Dopamine and Norepinephrine Release in the Rat Nucleus Accumbens and Prefrontal Cortex**
Paul Glaser, Washington University in St. Louis
- 12:55 PM – 12:59 PM **Dopamine Modulation of Action Control in a Rodent Model of Attention-Deficit/Hyperactivity Disorder**
Joman Natsheh, Center for Molecular and Behavioral Neuroscience, Rutgers University
- 1:00 PM – 1:04 PM **Regional Brain Network Organization Distinguishes the Combined and Inattentive Subtypes of Attention Deficit Hyperactivity Disorder**
Jacqueline Saad, The University of Sydney
- 1:05 PM – 1:09 PM **Lisdexamfetamine Targets Amygdala Mechanisms That Underlie the Emotional Bias of Cognitive Control: Relation to Clinical Improvement in Adults With ADHD**
Kurt Schulz, Icahn School of Medicine at Mount Sinai
- 1:10 PM – 1:14 PM **Attention Deficit/Hyperactivity Disorder, School Achievement and the Effect of Medication: Evidence From a Swedish Primary School Population**
Andreas Jangmo, Karolinska Institute
- 1:15 PM – 1:19 PM **The Association Between ADHD Medication and Seizures**
Kelsey Wiggs, Indiana University
- 12:30 PM – 2:30 PM **Poster Session With Lunch**
Exhibit Hall C
***See pages 55 through 67 for a complete listing of posters.

FULL SCHEDULE

Concurrent Symposia Sessions

2:30 PM – 4:30 PM ***ADHD and Technology: The Opportunities and Perils***
Thurgood Marshall Ballroom

Chair: Russell Schachar, University of Toronto

2:30 PM – 2:40 PM Introduction

2:40 PM – 3:00 PM ***Technology, Big Data, and Predicting Behavioral Health Measures***
Brenda Curtis, Perelman School of Medicine
University of Pennsylvania

3:00 PM – 3:20 PM ***Digital Therapeutics for the Treatment of ADHD: Results From a Large-Scale Randomized Clinical Trial***
Scott Kollins, Duke University

3:20 PM – 3:40 PM ***The Use of Big Data to Address Clinical Issues***
Joseph Biederman, Massachusetts General Hospital

3:40 PM – 4:00 PM ***Excessive Newborn Stimulation and Subsequent Attentional Capacity***
Dimitri Christakis, Seattle Children's Research Institute

4:00 PM – 4:30 PM Discussion

Overall Abstract: Every new technology created by mankind seems to afford advantages and disadvantages to society as a whole. Many recent technological developments can negatively impact people's mental health. The internet can become an obsession to the point of addiction, overstimulation arising from mobile devices and games can adversely impact attention, cognition, and sleep and social media are reshaping the way we relate to one another. Each of these effects are of substantial importance to mental health professionals. Paradoxically, these same devices, computers and media allow access to large scale data that is providing unrepresented new insights into the mechanism of mental illness, shaping new technology-

FULL SCHEDULE

based treatments for ADHD and creating new ways of communicating with our patients to promote positive health behaviors. ADHD scientists and practitioners have eagerly embraced these new technologies as this symposium will reveal. This symposium will address the potential of digital platforms to promote positive mental health in humans and overstimulation in animals, the effectiveness of specially designed computer games for treating the cognitive manifestations of ADHD, and the utility of electronic medical records (EMR) for evaluation of cardiac adverse effects of antidepressants in youth and for assessment of adherence to stimulant treatment in ADHD.

Learning Objectives:

- Be able to describe the results of recent trials of cognitive remediation for ADHD.
- Illustrate how electronic medical records can be used to address important clinical questions in ADHD.
- Be able to describe the effects of excessive non-normative stimulation during infancy.

2:30 PM – 4:30 PM

Outside the Pill Bottle: Assessment and Management of Adult ADHD

Lincoln 3-4

Chair: Mark Stein, University of Washington

2:30 PM – 2:40 PM

Introduction

2:40 PM – 3:00 PM

Collaboration Between Prescribers and Other Clinicians in Managing ADHD

Thomas Brown, Keck School of Medicine of University of Southern California

3:00 PM – 3:20 PM

If a Neuropsychological Evaluation is Not Needed for Diagnosis, What Does It Add to Diagnosis and Treatment of ADHD?

Jeanette Wasserstein, Mt. Sinai Medical College

3:20 PM – 3:40 PM

Still Distracted After All These Years: Exploring the World of ADHD After Age 60

Kathleen Nadeau, Chesapeake ADHD Center of Maryland

FULL SCHEDULE

3:40 PM – 4:00 PM ***Intentions Into Actions: CBT for Adult ADHD***
J. Russell Ramsay, University of Pennsylvania,
Perelman School of Medicine

4:00 PM – 4:30 PM Discussion

Overall Abstract: While multimodal treatment and collaboration between prescribers and mental health providers is common in pediatric ADHD, psychosocial treatment and collaborative and integrative care models are still emerging. The workshop will highlight complexities, barriers, and lessons learned in managing the adult ADHD patient as perspectives on diagnosis, management, and treatment will be provided by several non-prescribing providers.

Learning Objectives

- Increase familiarity with the presentation and evaluation of adults with ADHD, including role of testing.
- Describe psychotherapeutic approaches that compliment pharmacological interventions in the adult patient.
- Increase awareness of how ADHD presents in older adult compared to other age groups.

4:30 PM – 5:00 PM **Coffee Break**
Exhibit Hall C Foyer

5:00 PM – 6:15 PM **Ask the Experts: Psychosocial and Risk Prevention**
Hoover

Participants:

Kevin Antshel, Syracuse University
Russell Barkley, Virginia Commonwealth University Medical Center
Brooke Molina, University of Pittsburgh
Ronna Fried, Massachusetts General Hospital & Harvard Medical School

FULL SCHEDULE

5:00 PM – 6:15 PM

Ask the Experts: Pharmacotherapy
Coolidge

Participants:

Lenard Adler, NYU School of Medicine

Jay Giedd, University of California San Diego

Adelaide Robb, Children's National Health Systems

Timothy Wilens, Massachusetts General Hospital

Janet Wozniak, Massachusetts General Hospital

6:15 PM – 7:30 PM

Reception and Poster Viewing
Exhibit Hall C

SCHEDULE AT A GLANCE

SUNDAY, JANUARY 14, 2018

7:00 AM – 8:00 AM	International Committee Breakfast and Business Meeting (By Invitation) Coolidge
7:30 AM – 4:00 PM	Registration Open Thurgood Marshall Foyer – Mezzanine Level
7:30 AM – 8:30 AM	Morning Break Atrium Foyer outside of Exhibit Hall C
8:15 AM – 9:00 AM	APSARD Business Meeting Thurgood Marshall Ballroom
9:00 AM – 10:30 AM	Plenary Session: <i>Environmental and Genetic Influences on ADHD</i> Thurgood Marshall Ballroom
10:30 AM – 11:00 AM	Coffee Break Atrium Foyer outside of Exhibit Hall C
11:00 AM – 12:30 PM	Plenary Session: <i>ADHD as a Brain Disorder: Why is This So Difficult to Establish?</i> Thurgood Marshall Ballroom
12:30 PM – 2:30 PM	Lunch Session with Poster Viewing Exhibit Hall C

12:30 PM – 2:30 PM **Lunch Discussion Groups**

<i>ADHD in the Prison System</i>	<i>International Perspectives on ADHD</i>
Thurgood Marshall Ballroom	Lincoln 3-4

2:30 PM – 4:30 PM **Symposia Sessions**

<i>New Perspectives on ADHD and Mood Dysregulation</i>	<i>Emerging Evidence for the Effectiveness of ADHD Coaching</i>
Thurgood Marshall Ballroom	Lincoln 3-4

**Sunday,
January 14, 2018**

NOTES

FULL SCHEDULE

SUNDAY, JANUARY 14, 2018

7:00 AM – 8:00 AM	International Committee Breakfast and Business Meeting (By Invitation) Coolidge
7:30 AM – 4:00 PM	APSARD Registration Thurgood Marshall Foyer
7:30 AM – 8:30 AM	Morning Break Exhibit Hall C Foyer
8:15 AM – 9:00 AM	APSARD Business Meeting Thurgood Marshall Ballroom
9:00 AM – 10:30 AM	Plenary Session: <i>Environmental and Genetic Influences on ADHD</i> Thurgood Marshall Ballroom

Genetics and Environmental Factors

Chair: Jeffrey Newcorn, Mount Sinai Medical Center

ADHD: Progress in Identifying Genetic and Environmental Risk Factors

Anita Thapar, Cardiff University

Beyond Heritability – Have Studies of the Effects of Institutional Deprivation Changed How We Conceptualise ADHD?

Edmund Sonuga-Barke, King's College London

Overall Abstract: Although ADHD is a highly heritable disorder, simple genetic approaches have not been able to account for the disorder. Recent findings highlight the importance of complex genetic strategies and the aggregate effects of multiple genetic risk factors. There are also a number of well-documented environmental and psychosocial risk factors, which presumably augment, interact with and potentially modify genetic predisposition. This plenary session will explore genetic and environmental risk factors for ADHD, reviewing the latest findings regarding what is known about each. The session will additionally illustrate how recent genetic findings have been incorporated into large-scale epidemiologic studies (Thapar), and the longitudinal course of youth raised in extreme environments who suffered the effects of massive psychosocial deprivation (Sonuga-Barke).

FULL SCHEDULE

Learning Objectives:

- Attendees will learn about genetic loci that have been implicated in ADHD, and how these can be used in clinical and epidemiological research.
- Attendees will learn about leading environmental causes of ADHD, and the impact of extreme deprivation on the development of ADHD symptoms.

10:30 AM – 11:00 AM **Coffee Break**
Exhibit Hall C Foyer

11:00 AM – 12:30 PM **Plenary Discussion Session: *ADHD as a Brain Disorder: Why Is This So Difficult to Establish?***
Thurgood Marshall Ballroom

Chair: Stephen Faraone, SUNY Upstate Medical University

Participants:

Barbara Franke, Radboud University Medical Center
Stephen Faraone, SUNY Upstate Medical University
John Gabrieli, Massachusetts Institute of Technology
Jay Giedd, University of California San Diego

Overall Abstract: This plenary symposium will first briefly present the results of recent mega-analyses comparing brain volumes between ADHD patients and control participants. This will include previously published data about subcortical structures and new data about cortical structures. The controversy engendered by the subcortical publication will be described and then the plenary panel will present their views of the question “How do we view ADHD as a brain disorder in light of the ENIGMA ADHD results?” Each member of the panel will briefly present their views followed by a panel discussion and participation from the audience.

Learning Objectives:

- Learn about the results from the ENIGMA ADHD analysis of subcortical brain volumes.
- Learn about the results from the ENIGMA ADHD analysis of cortical brain volumes.
- Understand how the ENIGMA ADHD results inform us about the nature of brain abnormalities in ADHD.
- Understand the implications for future research.

12:30 PM – 2:30 PM **Lunch With Poster Viewing**
Exhibit Hall C

FULL SCHEDULE

Concurrent Lunch Discussion Groups

12:30 PM – 2:30 PM ***ADHD in the Prison System***
Thurgood Marshall Ballroom

Chair: Philip Asherson, Kings College London

Participants:

Barbara Franke, Radboud University Medical Center
Jeffrey Stein, Public Defender Service for the District of Columbia (PDS)
Steven Pliszka, UT Health Science Center at San Antonio

Overall Abstract: This symposium will consider the impact of ADHD in relation to adult offending behaviour. Around 20-30% of prisoners are known to meet diagnostic criteria for ADHD. Recent findings from national registry data in Sweden suggests that treatment of ADHD with stimulants or atomoxetine reduces criminal offences by between 30-40%; and reduces violent re-offending on release from prison. To date there has only been one randomised control trial of methylphenidate in prisoners with ADHD, that found a very large effect with a standardised mean difference greater than 2.0. Professor Asherson has completed a pilot study of young adult prisoners and found similar large effects, and is now leading a large-scale randomised control trial to clarify how large are the medication effects compared to placebo. This work suggests that treating ADHD can lead to reductions in criminal behaviour. Independent review from prison inspectors in the UK also noted improvements in behaviour that were highly significant for some prisoners on the ADHD treatment program. Their main concern was the access to treatment and social support would be needed to maintain these benefits on release of patients with ADHD into the community. Although there have been concerns about the potential abuse of ADHD medications in the prison environment, most cases titrated to very low doses, and did not show drug seeking behaviour. Overall the risks of abuse in prison settings appears to be low and no higher than that seen for other ADHD medications.

This symposium will start with a description of these studies of offenders with ADHD from Professor Asherson. The second speaker is Professor Barbara Franke, a leading ADHD investigator based in the Netherlands. Barbara leads the Aggessotype project, a large consortium funded by the European Union to investigate the genetic and neuropathological aetiology of aggression, and the development of novel drug and non-drug treatments such as neurofeedback. The third speaker, Jeff Stein, is a public defender

FULL SCHEDULE

who says that almost all the people he works with have a history of ADHD plus oppositional defiant disorder. He will give his perspective as someone involved in the legal profession.

This symposium will discuss the association of ADHD to criminal behaviour, the delivery of medication treatment in prison settings, and the effects of treatment, and consider the impact of ADHD from a legal perspective. We aim for an interactive discussion with the audience that will highlight the importance of diagnosing and treating ADHD among offenders.

Learning Objectives:

- That 20-30% of prisoners meet criteria for ADHD.
- That treatment of ADHD leads to reductions in criminal behavior.
- That treatments for ADHD can be delivered safely in prison settings.
- The impact of ADHD in the legal system.

12:30 PM – 2:30 PM

International Perspectives on ADHD

Lincoln 3-4

Chair: Margaret Weiss, University of Arkansas Medical Sciences

Participants:

Iris Manor, Geha MHC

J.J. Sandra Kooij, PsyQ, Program Adult ADHD, The Hague

César Soutullo, University of Navarra Clinic DR

Takuya Saito, Hokkaido University, Graduate School of Medicine

Edmund Sonuga-Barke, King's College London

Overall Abstract: This symposium takes advantage of the presence of International leaders in the area of ADHD to open discussion about local strengths and challenges in the area of ADHD in different parts of the world. Each speaker will give a brief presentation of key strengths and challenges unique to their location, followed by open discussion of regional differences with audience participation.

Learning Objectives:

- Raise awareness of both the similarities and differences of ADHD in North America, Europe, Asia, the Middle East and the British Isles.
- Identify unique local challenges and strengths that can inform a knowledge exchange in which we learn from each other.
- Discuss collaborative initiatives to help grow a global network out of current national networks and facilitate global targets for improved care.

FULL SCHEDULE

Concurrent Symposia and Workshop Sessions

2:30 PM – 4:30 PM ***New Perspectives on ADHD and Mood Dysregulation***
Thurgood Marshall Ballroom

Chair: Andrew Nierenberg, Massachusetts General Hospital

2:30 PM – 2:40 PM Introduction

2:40 PM – 3:00 PM ***An Overview of Emotional Dysregulation in ADHD***
Anthony Rostain, University of Pennsylvania,
Perelman School of Medicine

3:00 PM – 3:20 PM ***Deficient Emotional Self-Regulation in the Context of ADHD***
Joseph Biederman, Massachusetts General Hospital

3:20 PM – 3:40 PM ***Affective Circuitry and ADHD***
Jonathan Posner, Columbia University

3:40 PM – 4:00 PM ***Emotional Lability in ADHD***
Argyris Stringaris, National Institute of Mental Health

4:00 PM – 4:30 PM Discussion

Overall Abstract: While problems with emotional control are not a defining feature of ADHD, they occur in a large number of individuals with ADHD and are frequently associated with a high degree of impairment. Consistent with these clinical findings, studies of underlying neurobiological mechanisms in ADHD point to abnormalities of motivation and emotional regulation, and not just attention and inhibitory control. Yet, it is unknown whether the neural underpinnings of emotional lability in ADHD are unique to ADHD or reflect common features seen across a multiplicity of diagnostic entities. This symposium will examine the nature of emotional dysregulation in youth and adults with ADHD and other disorders, and describe the clinical and neurobiological features which characterize affected individuals.

FULL SCHEDULE

Learning Objectives:

- Attendees will appreciate the nature of emotional dysregulation in youth with ADHD and learn how the clinical features of emotional dysregulation in youth and adults with ADHD are similar to or different from the characteristics of emotional dysregulation in other disorders.
- Attendees will appreciate the neurobiological mechanisms underlying emotional dysregulation in youth and adults with ADHD and other disorders.

2:30 PM – 4:30 PM

Emerging Evidence for the Effectiveness of ADHD Coaching

Lincoln 3-4

Chair: Jodi Sleeper-Triplett, JST Coaching & Training

Participants:

Jodi Sleeper-Triplett, JST Coaching & Training

Elizabeth Ahmann, Maryland University of Integrative Health

Lisa Tuttle, University of Pennsylvania

Overall Abstract: ADHD coaching, which emerged in the 1990s, is a nonclinical behavioral modality that can complement the work of clinicians to improve the performance and well-being of individuals with ADHD across the lifespan.

Coaching is a client-centered wellness model predicated on the view that those coached are creative, resourceful, and whole (Sleeper-Triplett, 2010). In contrast to academic services such as tutoring or learning-strategy instruction, coaching does not prescribe the same set of steps to all participants (e.g., Allsopp, Minskoff, & Bolt, 2005). Instead, coaches are trained to use Socratic questioning and active listening to prompt awareness, reflection, and planning. This process facilitates a client's ability to clarify personal goals and create realistic plans for achieving them, fostering self-determination.

As with health and wellness coaching, ADHD coaching typically incorporates elements of life coaching, skills coaching, and psychoeducation (Wright, 2014). It draws on current knowledge of the deficits associated with ADHD to inform the coaching relationship co-developed by client and coach (Sleeper-Triplett, 2010). By design, coaching provides a high level of structure and accountability to (a) assist in goal identification, (b) foster behavioral change and goal attainment, (c) promote improvements in functional arenas, and (d) reinforce the maintenance of gains, including

FULL SCHEDULE

those made in other therapeutic modalities. As such, ADHD coaching is increasingly recognized in the clinical literature as a useful and important component of multimodal treatment (e.g., Barkley, 2015; Kooij et al., 2010; Prevatt & Levrini, 2015; Ramsay, 2010).

This data-driven presentation will provide an overview of ADHD coaching, propose how coaching fits within a multimodal treatment approach, demonstrate the process of ADHD coaching, and provide a descriptive review of extant research (Ahmann et al., 2017; Ahmann et al., in press; Tuttle et al., 2016). A review of the literature to date suggests that ADHD coaching may hold promise in improving functional outcomes and quality of life across the lifespan and contribute positively to multimodal treatment approach.

Learning Objectives:

- Describe three or more aspects of the ADHD coaching process.
- Identify several client outcomes supported by ADHD coaching research.
- Draw conclusions about the potential value of ADHD coaching in multimodal treatment approaches.

NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

POSTERS

1. **Diagnosis and Treatment Options for Preschoolers With ADHD**

Sharon Wigal¹, Phillip Chappell², Donna Palumbo^{*2}, Shannon Lubaczewski², Sara Ramaker², Richat Abbas²

¹AVIDA Inc., ²Pfizer Inc

2. **Barriers to Evidence-Based ADHD Care for Parents of At-Risk Children**

Tamara Abu-Ramadan^{*1}, Lea Taylor¹, Yelim Chung¹, Avery Albert¹, Kevin Antshel¹

¹Syracuse University

3. **Multimodal Psychiatrist-Coach Intervention for ADHD: Case Report Using CARE Guidelines**

Elizabeth Ahmann^{*1}, Katherine Smith¹, Laurie Ellington¹, Rebecca O. Pille¹

¹Maryland University of Integrative Health

4. **The Impact of Positive Illusory Bias on Treatment Outcomes Among Adolescents With ADHD**

Avery Albert^{*1}, Lea Taylor¹, Tamara Abu-Ramadan¹, Kevin Antshel¹

¹Syracuse University

5. **Multimodal Approach for College Students With ADHD: Combining Exercise and ADHD Coaching**

Kari Lewis^{*1}

¹ADHD Behavior Education Services, North Carolina State University

6. **Investigation of Clinical Practice Challenges in the Management of ADHD**

Greg Mattingly^{*1}, Rakesh Jain², Jani Hegarty³, Quentin O'Brien³

¹St. Charles Psychiatric Associates, ²Texas Tech Health Sciences, ³Health and Wellness Partners

7. **A Pilot Trial of a Joint Psychosocial Intervention for Behavior and Sleep in Children With a Disruptive Behavior Disorder (DBD)**

Sara Mills^{*1}, Brianna Bendixsen², Sue Calhoun¹, Daniel Waschbusch¹, James Waxmonsky¹

¹Pennsylvania State University, College of Medicine, ²Pennsylvania State University, Harrisburg

POSTERS

8. Goal Orientation and Stimulant Misuse in College Students

Lea Taylor*¹, Avery Albert¹, Tamara Abu-Ramadan¹, Kevin Antshel¹

¹Syracuse University

9. Evidence of Poor Patient Engagement in Treatment for ADHD: A 17-Year Electronic Medical Records Data Mining Study From a Large Health Care Organization

Ronna Fried*¹, Joseph Biederman¹, Maura Fitzgerald², Barbara Storch², Alexa Pulli², K. Yvonne Woodworth², Roy Perlis¹

¹Massachusetts General Hospital & Harvard Medical School,

²Massachusetts General Hospital

10. The Clinical Correlates of Working Memory Deficits in Youth With ADHD: A Comprehensive Literature Review

Ronna Fried*¹, Jessica Abrams², James Chan², Anna Hall², Leah Feinberg², Amanda Pope², Barbara Storch², Stephen Faraone³, Joseph Biederman¹

¹Massachusetts General Hospital & Harvard Medical School,

²Massachusetts General Hospital, ³SUNY Upstate Medical University

11. The Relationship and Predictive Value of Core ADHD Symptoms and Executive Function Deficits

Michael Silverstein¹, Stephen Faraone², Terry L. Leon³, Thomas Spencer⁴, Joseph Biederman⁴, Lenard Adler*³

¹Drexel University, ²SUNY Upstate Medical University, ³NYU School of Medicine, ⁴Massachusetts General Hospital

12. Do Subsyndromal Manifestations of MDD in Children at Genetic Risk for MDD Predict the Development of Major Depression? A Five-Year Longitudinal Controlled Study

Joseph Biederman*¹, Mai Uchida, MD², Maura Fitzgerald¹, Caroline Kelberman¹, Hilary Woodworth¹, Nicholas Carrellas¹

¹Massachusetts General Hospital, ²Massachusetts General Hospital & Harvard Medical School

POSTERS

13. Sport Concussion and Attention Deficit Hyperactivity Disorder in Student Athletes: A Cohort Study

Joseph Biederman*¹, Mary Alexis Iaccarino², Maura Fitzgerald¹, Alexa Pulli¹, K. Yvonne Woodworth¹, Thomas J. Spencer³, Ross Zafonte⁴

¹Massachusetts General Hospital, ²Spaulding Rehabilitation Hospital & MassGeneral Hospital for Children, ³Massachusetts General Hospital & Harvard Medical School, ⁴Spaulding Rehabilitation Hospital

14. Predictive Utility of Autistic Traits in Youth With ADHD: A Controlled 10-Year Longitudinal Follow-Up Study

Gagan Joshi¹, Maura Fitzgerald², Stephen Faraone³, Janet Wozniak¹, Ronna Fried¹, Maribel Galdo¹, Abigail Belser², Barbora Hoskova², Melissa De Leon², Joseph Biederman*¹

¹Harvard Medical School, Massachusetts General Hospital,

²Massachusetts General Hospital, ³SUNY Upstate Medical University,

15. Parental Stigma About Medical and Mental Health Issues: An Investigation Into the Differential Effects of Parent Gender and Stigma on ADHD Vs. Asthma

Yelim Chung*¹, Tamara Abu-Ramadan¹, Lea Taylor¹, Kevin Antshel¹

¹Syracuse University

16. The Impact of ADHD in the Canadian Workplace

Kathryn Fotinos¹, Alexa Fine¹, Tia Sternat¹, Irvin Epstein¹, Martin Katzman*¹

¹START Clinic for Mood and Anxiety Disorders

17. Reward-Based Learning and the Severity of Substance Abuse Risk in Drug-Naive Youth

Iliyan Ivanov*¹, Muhammad Parvaz², Kristen Kim³, Jeffrey Newcorn²

¹Mt. Sinai NYC, ²Icahn School of Medicine at Mount Sinai, ³Rutgers University

18. Sluggish Cognitive Tempo Predicts Academic Fluency in Clinically-Referred Youth, Beyond Contributions of Core Skills, Inattention, and Graphomotor Speed

Lisa Jacobson*¹, Mark Mahone²

¹Johns Hopkins School of Medicine, Kennedy Krieger Institute, ²Kennedy Krieger Institute

POSTERS

19. The Social Context of Alcohol Use Among Young Adults With ADHD Histories

Traci Kennedy*¹, Christine Walther², Sarah Pedersen¹, Kirsten McKone¹, Elizabeth Gnagy³, William Pelham³, Brooke Molina¹

¹University of Pittsburgh, ²University of Houston, Clear Lake, ³Florida International University

20. Young Adult Outcomes as a Function of Adolescent ADHD Symptom Trajectories: Inattention, Hyperactivity/Impulsivity, and Oppositional Behavior

Traci Kennedy*¹, Christine Walther², Sarah Pedersen¹, Kirsten McKone¹, Elizabeth Gnagy³, William Pelham³, Brooke Molina¹

¹University of Pittsburgh, ²University of Houston, Clear Lake, ³Florida International University

21. Is SCT a Risk Factor for Internalizing Psychopathology?

Keith McBurnett*¹, Shaikh Ahmahdh¹, Lauren Friedman¹, Miguel Villodas², Linda Pfiffner¹

¹University of California, San Francisco, ²San Diego State University

22. Prevalence and Impact of Under- or Misdiagnosed ADHD in Adults Referred for the Treatment of Mood and Anxiety Disorders

Tia Sternat*¹, Kathryn Fotinos¹, Alexa Fine¹, Cathy Cameron¹, Irvin Epstein¹, Martin Katzman¹

¹START Clinic for Mood and Anxiety Disorders

23. Attention Deficit Hyperactivity Disorder: A Predictive Factor of Treatment-Resistance in Adults Diagnosed With Generalization Anxiety Disorder

Tia Sternat*¹, Alexa Fine¹, Kathryn Fotinos¹, Irvin Epstein¹, Martin Katzman¹

¹START Clinic for Mood and Anxiety Disorders

24. Longitudinal Relation Between Infant Motor Activity and Childhood ADHD Symptoms: Moderation by Maternal Sensitivity

Natalie Miller*¹, Andrea Chronis-Tuscano¹, Kathryn Degnan², Nathan Fox¹

¹University of Maryland - College Park, ²Catholic University of America

POSTERS

25. Emotion Dysregulation Increases in Cigarette Smokers With ADHD After Smoking Abstinence

John Mitchell^{*1}, Carl Lejuez², F. Joseph McClernon¹, Jean Beckham³, Scott Kollins¹

¹Duke University Medical Center, ²University of Kansas, ³Durham, NC Veterans Affairs Medical Center

26. OPEN BOARD

27. Descriptive Study of Friendships and Social Networks of Adolescents With ADHD

Barbara Wise^{*1}

¹Indiana Wesleyan University

28. Further Evidence of High Level of Persistence of Pediatric Bipolar-I Disorder From Childhood Onto Late Adolescent YEARS: A One Year Replication Longitudinal Follow-Up Study

Janet Wozniak^{*1}, Rebecca Wolenski¹, Maura Fitzgerald¹, Stephen Faraone², Gagan Joshi³, Mai Uchida³, Joseph Biederman³

¹Massachusetts General Hospital, ²SUNY Upstate Medical University,

³Massachusetts General Hospital & Harvard Medical School

29. OPEN BOARD

30. Does Exposure to Parental Substance Use Disorders Increase Offspring Risk for a Substance Use Disorder? A Longitudinal Follow-Up Study Into Young Adulthood

Amy Yule^{*1}, Timothy Wilens¹, MaryKate Martelon², Joseph Biederman¹

¹Harvard Medical School & Massachusetts General Hospital,

²Massachusetts General Hospital

31. Further Evidence of the Diagnostic Utility of the Child Behavior Checklist for Identifying Pediatric Bipolar I Disorder

Amy Yule^{*1}, Maura Fitzgerald², Timothy Wilens¹, Janet Wozniak¹, K.

Yvonne Woodworth², Alexa Pulli², Mai Uchida¹, Stephen Faraone³, Joseph Biederman¹

¹Harvard Medical School & Massachusetts General Hospital,

²Massachusetts General Hospital, ³SUNY Upstate Medical University & University of Bergen, Norway

POSTERS

32. Screening for ADHD and Impairment in a General Outpatient Psychiatric Sample of Adults

Dara Babinski*¹, James Waxmonsky², Edward Bixler², Duanping Liao², Amanda Pearl², Dahlia Mukherjee², Daniel Waschbusch², Erika Saunders²
¹Penn State College of Medicine, ²Pennsylvania State University, College of Medicine

33. Item Response Theory Analysis of the Before School Functioning Questionnaire and Parent Rating of Evening and Morning Behavior Scale, Revised in Children With Attention-Deficit/Hyperactivity Disorder

Stephen Faraone*¹, Norberto DeSousa², F. Randy Sallee², Bev Incledon², Timothy Wilens³
¹SUNY Upstate Medical University, ²Ironshore Pharmaceuticals & Development, Inc., ³Harvard Medical School/Massachusetts General Hospital

34. Social Anxiety and Self-Efficacy in Young Adults With ADHD Symptoms: Assessing the Use of the Adult ADHD Self-Report Scale (ASRS-V1.1) Part A

Tom Buchanan¹, Meghan Leahy*², Roberta Waite³
¹Mount Royal University, ²Leahy Learning, ³Drexel University

35. Sluggish Cognitive Tempo in Adult Outpatients Seeking an ADHD Evaluation: A Psychometric Analysis of the BAARS-IV SCT Subscale

Jessica Lunsford-Avery*¹, Scott Kollins¹, Julia Schechter¹, Maggie Sweitzer¹, Cara Lusby¹, Jessica Solis Sloan¹, John Mitchell¹
¹Duke University Medical Center

36. Latent Class Analysis of Previsit Parent Ratings as Predictors of ADHD Comorbidities

Alison Pritchard*¹, Luke Kalb¹, T. Andrew Zabel¹, Lisa Jacobson¹
¹Kennedy Krieger Institute

37. Caregiver Survey of the Burden of Disease in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Brigitte Robertson*¹, Alexandra Khachatryan¹, Michael Andreini², Steven Blahut², Eitan Shimko², Robert Stolper², Peter S. Jensen³
¹Shire, ²Quintiles IMS, ³University of Arkansas for Medical Sciences

POSTERS

38. At-Home Functional Impairment in Youth With ADHD: Factor Structure and Norm-Referenced Cut-Off Points for the Before School Functioning Questionnaire and Parent Rating of Evening and Morning Behavior Scale, Revised

Stephen V. Faraone¹, Norberto DeSousa², Rick Nullmeier², Randy Sallee^{*2}, Beverly Incledon², Timothy Wilens³

¹SUNY Upstate Medical University, ²Ironshore Pharmaceuticals & Development, Inc., ³Harvard Medical School/Massachusetts General Hospital

39. ADHD Symptoms and Performance on the Children's Gambling Task

Sierra Tolbert^{*1}, Caroline Barry¹, Victoria Saba¹, Alesha Majors¹, Bernard Fuemmeler², Scott Kollins¹, Julia Schechter¹

¹Duke University Medical Center, ²Virginia Commonwealth University

40. Response Time Adjustment in the Stop Signal Task Serve as a Marker of Reinforcement Learning: Development in Typically Developing and ADHD Children and Adolescents

Russell Schachar^{*1}, Annie Dupuis², Jennifer Crosbie¹, Paul Arnold³, Mohsen Soltanifar¹

¹University of Toronto, ²The Hospital for Sick Children, ³University of Calgary

41. Copy Number Variants in Brain-Related Genes Are Associated With Neuropsychiatric Traits in Childhood

Russell Schachar^{*1}, Christie Burton¹, Mehdi Zarrei¹, W. Engchuan¹, Daniel Merico¹, J. MacDonald¹, B. Xiao¹, Andrew Paterson¹, Lisa Strug¹, Christian Marshall¹, Jennifer Crosbie¹, Paul Arnold², Steven Scherer¹

¹University of Toronto, ²University of Calgary

42. Heritability of Neuropsychological Subtypes in ADHD

Anne Arnett^{*1}, Bruce Pennington², Erik Willcutt³

¹University of Washington, ²University of Denver, ³University of Colorado

43. Reverse Microdialysis Studies of d-, l-, & d,l-Amphetamine-Evoked Dopamine and Norepinephrine Release in the Rat Nucleus Accumbens and Prefrontal Cortex

Paul Glaser^{*1}, Peter Huetti², Francois Pomerleau², Luke Bradley², Meagan Littrell², Greg Gerhardt²

¹Washington Univ. in St. Louis, ²University of Kentucky

POSTERS

44. Dopamine Modulation of Action Control in a Rodent Model of Attention-Deficit/Hyperactivity Disorder

Joman Natsheh^{*1}, Michael Shiflett², Marwa Abdelaziz², Emaan Chaudhry², Samantha Devalaraju², Delia Duran², Victor Lopez², Sydney Pacelli²

¹Center for Molecular and Behavioral Neuroscience, Rutgers University,

²Rutgers University

45. The Endocytic Regulation of Autophagy and Cell Survival: Pathway Interactions for ADHD- and Autism-Risk Gene SLC9A9

Jameson Patak^{*1}, Jonathon Hess¹, Yanli Zhang-James¹, Stephen Glatt¹, Stephen Faraone¹

¹SUNY Upstate Medical University

46. Regional Brain Network Organization Distinguishes the Combined and Inattentive Subtypes of Attention Deficit Hyperactivity Disorder

Jacqueline Saad^{*1}, Kristi Griffiths², Michael Kohn³, Simon Clarke³, Leanne Williams⁴, Mayuresh Korgaonkar²

¹The University of Sydney, ²Brain Dynamics Centre, The Westmead Institute for Medical Research, The University of Sydney, ³Centre for Research into Adolescents' Health, Westmead Hospital, ⁴Stanford University

47. Lisdexamfetamine Targets Amygdala Mechanisms That Underlie the Emotional Bias of Cognitive Control: Relation to Clinical Improvement in Adults With ADHD

Kurt Schulz^{*1}, Beth Krone¹, Lenard Adler², Anne-Claude Bedard³, Juan Pedraza¹, Jeffrey Newcorn⁴

¹Icahn School of Medicine at Mount Sinai, ²NYU School of Medicine,

³University of Toronto, ⁴Mount Sinai Medical Center

48. Searching for Neural Biomarkers of the Risk for Pediatric Mood Disorders: A Controlled fMRI Study in Children

Joseph Biederman^{*1}, Mai Uchida², Yuwen Hung³, Caroline Kelberman¹, Schuyler Gaillard³, John D. E. Gabrieli³

¹Massachusetts General Hospital, ²Massachusetts General Hospital & Harvard Medical School, ³Massachusetts Institute of Technology

POSTERS

49. A Prospective Open-Label Trial of Extended-Release Liquid Methylphenidate for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Adults With High-Functioning Autism Spectrum Disorder: An Interim Analysis

Gagan Joshi¹, Barbora Hoskova², Maura Fitzgerald², Tolga Atilla Ceranoglu¹, Amy Yule¹, Craig Surman², Ronna Fried¹, Maribel Galdo¹, Abigail Belser², Melissa De Leon², Joseph Biederman^{*1}

¹Harvard Medical School & Massachusetts General Hospital,

²Massachusetts General Hospital

50. Therapeutic Response and Side-Effects to Methylphenidate in ADHD: Role of Gender of the Child and the Observer

Venkat Bhat^{*1}, Natalie Grizenko², Ridha Joobar²

¹University of Toronto, ²McGill University

51. Therapeutic Response and Side-Effects in Children With ADHD: Role of Observation Setting

Venkat Bhat^{*1}, Natalie Grizenko², Ridha Joobar²

¹University of Toronto, ²McGill University

52. Therapeutic Response and Side-Effects to Methylphenidate in ADHD: Role of Co-Morbidity

Venkat Bhat^{*1}, Natalie Grizenko², Ridha Joobar²

¹University of Toronto, ²McGill University

53. Single- and Multiple-Dose Pharmacokinetics of KP415, a Novel d-Methylphenidate Product Containing a Prodrug of d-Methylphenidate, in Healthy Volunteers

Rene Braeckman¹, Sven Guenther¹, Travis Mickle¹, Andrew Barrett^{*1}, Adam Smith¹, Kathryn Roupe², Michael Nutt², Cynthia Zamora²

¹KemPharm, Inc., ²Worldwide Clinical Trials

54. Relationships Between Executive Function Improvement and ADHD Symptom Improvement With Lisdexamfetamine Dimesylate in Adults With ADHD and Executive Function Deficits: A Post Hoc Analysis

Thomas Brown^{*1}, Yi Chen², Victor Otcheretko², Brigitte Robertson²

¹Keck School of Medicine of University of Southern California, ²Shire

POSTERS

55. Efficacy and Safety of SPN-810 (Extended-Release Molindone) to Treat Impulsive Aggression in Children Being Optimally Treated for Attention-Deficit/Hyperactivity Disorder: Phase 2b and Open-Label Extension Results

Gianpiera Ceresoli-Borroni^{*1}, Toyin Adewole¹, Tesfaye Liranso¹, Robert Findling²

¹Supernus Pharmaceuticals, Inc., ²Kennedy Krieger Institute/Johns Hopkins University

56. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of SHP465 Mixed Amphetamine Salts Extended-Release in Children and Adolescents With ADHD: Exploratory Analyses by Age Group

Ann Childress^{*1}, Ming Yu², Brian Yan², Brigitte Robertson²

¹Center for Psychiatry and Behavioral Medicine, Inc., ²Shire

57. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children With ADHD

Ann Childress^{*1}, Sally A. Berry², Antonio Pardo², Heidi W. Belden²

¹Center for Psychiatry and Behavioral Medicine, Inc., ²Tris Pharma, Inc.

58. Efficacy, Safety, and Tolerability of an Extended-Release, Orally Disintegrating Methylphenidate Tablet in Children 6–12 Years of Age With ADHD: Open-Label, Dose-Optimization Period Outcomes

Ann Childress^{*1}, Scott H. Kollins², Andrew J. Cutler³, Andrea Marraffino⁴, Carolyn R. Sykes⁵

¹Center for Psychiatry and Behavioral Medicine, Inc., ²Duke University,

³Meridien Research, ⁴Florida Clinical Research Center, LLC, ⁵Neos Therapeutics, Inc.

59. Approached to Share or Sell Your Meds? College Students With ADHD and Substance-Tolerant Social Environments

Montaya Dawkins^{*1}, Heather Joseph², Heidi Kipp³, Engster Stacey⁴, Rachel Lindstrom³, Seth Harty⁵, Bridget Newman⁶, Srihari Bangalor⁷, Brooke Molina⁸

¹University of Pittsburgh Medical Center, Western Psychiatric Institute & Clinic, ²University of Pittsburgh School of Medicine, ³University of Pittsburgh Medical Center, Western Psychiatric Institute & Clinic,

⁴University of Pittsburgh Medical Center, ⁵University of Canterbury, ⁶RTI International, ⁷Roseville Medical Center, ⁸University of Pittsburgh

POSTERS

60. Executive Functioning in Everyday Life in Emerging Adults With ADHD

Ronna Fried*¹, Robert Roth², Peter Isquith³, Maura Fitzgerald⁴, Heidi Boland⁴, Joseph Biederman¹

¹Massachusetts General Hospital & Harvard Medical School, ²Geisel School of Medicine at Dartmouth, ³Harvard Medical School & Geisel School of Medicine at Dartmouth, ⁴Massachusetts General Hospital

61. Modeling the Trajectory of ADHD Symptoms Throughout the Day in Children Treated With Placebo in a Laboratory Classroom Setting Study

Roberto Gomeni*¹, Seth Hopkins², Antony Loebel², Kenneth Koblan²

¹PharmacoMetrica, ²Sunovion Pharmaceuticals Inc.

62. Modeling Exposure-Response of Dasotraline on ADHD Symptoms Throughout the Day in Children With ADHD in a Laboratory Classroom Setting Study

Seth Hopkins*¹, Roberto Gomeni², Antony Loebel¹, Kenneth Koblan¹

¹Sunovion Pharmaceuticals Inc., ²PharmacoMetrica

63. Comparative Bioavailability of DR/ER-MPH, a Delayed-Release and Extended-Release Methylphenidate Formulation, and an Immediate-Release Methylphenidate in Healthy Adult Volunteers

Bev Incledon*¹, Norberto DeSousa¹, F. Randy Sallee¹

¹Ironshore Pharmaceuticals & Development Inc.

64. Attention Deficit/Hyperactivity Disorder, School Achievement and the Effect of Medication: Evidence From a Swedish Primary School Population

Andreas Jangmo*¹, Amanda Stålhandske¹, Ralf Kuja-Halkola¹, Henrik Larsson²

¹Karolinska Institute, ²Karolinska Institute & Örebro University

65. Double-Blind Sham-Controlled Pilot Study of Trigeminal Nerve Stimulation (TNS) for Attention-Deficit/Hyperactivity Disorder (ADHD)

James McGough*¹, Sandra Loo¹, Jennifer Cowen¹, Alexandra Sturm¹, Ian Cook¹

¹David Geffen School of Medicine at UCLA

POSTERS

66. ADAIR: An Abuse Deterrent Oral Formulation of Immediate Release Dextro-Amphetamine Sulfate (d-Amphetamine)

Jonathan Rubin^{*1}, David Siner², David Baker²

¹Consultant, ²Alcobra Pharma

67. Understanding Abuse Risk Related to Immediate-Release Amphetamine

Jonathan Rubin^{*1}, David Baker², David Siner², Natasha Oyedele³

¹Consultant, ²Alcobra Pharma, ³Inflexxion

68. A Randomized, Open-Label Bioequivalence Study of a New Extended-Release Amphetamine Oral Suspension in Adults

Carolyn Sikes^{*1}, Jeffrey Stark², Russ McMahan¹, Dorothy Engelking¹

¹Neos Therapeutics, ²Worldwide Clinical Trials,

69. Pharmacoscintigraphic and Pharmacokinetic Analysis of CTx-1301, a Novel Tri-Modal Oral Formulation for Release of Dexmethylphenidate in Healthy Adults

Raul Silva^{*1}, Matt Brams¹, Arthur Straughn¹, Shane Schaffer¹, Steven Abele¹, Howard Stevens², Neil Masson³

¹Cingulate Therapeutics, ²BDD Pharma, ³Royal College of Psychiatrists

70. L-Methylfolate Supplementation to Oros-Methylphenidate Pharmacotherapy in ADHD: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Craig Surman^{*1}, Tolga Atilla Ceranoglu¹, Carrie Vaudreuil¹, Brittany Albright¹, Mai Uchida¹, Amy Yule¹, Andrea Spencer¹, Heidi Boland¹, Rebecca Grossman¹, Lauren Rhodewalt¹, Maura Fitzgerald¹, Joseph Biederman¹

¹Massachusetts General Hospital

71. Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With ADHD

Nathan Teuscher^{*1}, Carolyn Sikes², Russ McMahan², Dorothy Engelking²

¹Certara, ²Neos Therapeutics

POSTERS

72. Efficacy and Safety of Dasotraline in Children With Attention Deficit Hyperactivity Disorder: A Laboratory Classroom Study

Sharon Wigal¹, Seth Hopkins², Kenneth Koblan², Ann Childress³, Joyce Tsai², Jay Hsu², Antony Loebel², Robert Goldman^{*2}

¹AVIDA Inc., ²Sunovion Pharmaceuticals Inc., ³Center for Psychiatry and Behavioral Medicine, Inc.,

73. Dasotraline for the Treatment of Attention Deficit Hyperactivity Disorder in Adults: Pooled Analysis of Two Double-Blind Studies

Lenard Adler¹, Scott Kollins², Seth Hopkins³, Robert Goldman³, Joyce Tsai³, Jay Hsu³, Andrei Pikalov^{*3}, Kenneth Koblan³, Antony Loebel³

¹New York University Langone Medical Center, ²Duke University Medical Center, ³Sunovion Pharmaceuticals Inc.

74. Efficacy, Safety, Tolerability and PK of Mazindol Controlled Release (CR) in Adults With ADHD

Tim Wigal^{*1}, Jeffrey Newcorn², Sharon Wigal¹, Nelson Handal³, Iouletta Mulligan⁴, Virginia Schmith⁵, Eric Konofal⁶

¹Avida, ²Mount Sinai Medical Center, ³Dothan Behavioral Medicine Clinic, ⁴Worldwide Clinical Trials, ⁵Nuventra Pharma Sciences, ⁶Pediatric Sleep Disorders Center

75. The Association Between ADHD Medication and Seizures

Kelsey Wiggs^{*1}, Zheng Chang², Patrick Quinn¹, Kwan Hur³, Robert Gibbons³, David Dunn⁴, Isabell Brikell², Henrik Larsson⁵, Brian D'Onofrio¹

¹Indiana University, ²Karolinska Institute, ³University of Chicago, ⁴Indiana University School of Medicine, ⁵Karolinska Institute & Örebro University

76. Clinically Meaningful Improvements With DR/ER-MPH in At-Home Functional Impairment During the Early Morning, Late Afternoon, and Evening in Children With Attention-Deficit/Hyperactivity Disorder

Timothy Wilens^{*1}, Stephen V. Faraone², Paul Hammerness³, Steven Pliszka⁴, Norberto DeSousa⁵, F. Randy Sallee⁵, Bev Incledon⁵, Jeffrey Newcorn⁶

¹Massachusetts General Hospital, ²SUNY Upstate Medical University, ³Harvard Medical School, ⁴UT Health Science Center at San Antonio, ⁵Ironshore Pharmaceuticals & Development, Inc., ⁶Mount Sinai Medical Center

NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

AUTHOR INDEX

Abbas, Richat	55	Chang, Zheng	67
Abdelaziz, Marwa	62	Chappell, Phillip	55
Abele, Steven	66	Chaudhry, Emaan	62
Abrams, Jessica	56	Chen, Yi	63
Abu-Ramadan, Tamara	55, 56, 57	Childress, Ann	64, 67
Adewole, Toyin	64	Chiu, Lisa	23
Adler, Lenard	23, 44, 56, 62, 67	Christakis, Dimitri	41
Ahmahdh, Shaikh	58	Chronis-Tuscano, Andrea	58
Ahmann, Elizabeth	52, 55	Chung, Yelim	55, 57
Albert, Avery	55, 56	Clarke, Simon	62
Albright, Brittany	66	Cook, Ian	65
Andreini, Michael	60	Cowen, Jennifer	65
Antshel, Kevin	43, 55, 56, 57	Crosbie, Jennifer	61
Arnett, Anne	61	Curtis, Brenda	41
Arnold, Paul	61	Cutler, Andrew J.	64
Asherson, Philip	10, 33, 49	Dawkins, Montaya	64
Babinski, Dara	60	Degnan, Kathryn	58
Baker, David	66	De Leon, Melissa	57, 63
Bangalor, Srihari	64	DeSousa, Norberto	60, 61, 65, 67
Barkley, Russell	14, 37, 43	Devalaraju, Samanthaika	62
Barrett, Andrew	63	D'Onofrio, Brian	15, 37, 67
Barry, Caroline	61	Dunn, David	67
Beckham, Jean	59	Dupuis, Annie	61
Bedard, Anne-Claude	62	Duran, Delia	62
Belden, Heidi W.	64	Ellington, Laurie	55
Belser, Abigail	57, 63	Engchuan, W.	61
Bendixsen, Brianna	55	Engelking, Dorothy	66
Berry, Sally A.	64	Epstein, Irvin	57, 58
Bhat, Venkat	9, 63	Faraone, Stephen	8, 18, 24, 48, 56, 57, 59, 60, 61, 62, 67
Biederman, Joseph	8, 23, 39, 41, 51, 56, 57, 59, 62, 63, 65, 66	Feinberg, Leah	56
Bixler, Edward	60	Findling, Robert	24, 64
Blahut, Steven	60	Fine, Alexa	57, 58
Boland, Heidi	65, 66	Fitzgerald, Maura	56, 57, 59, 63, 65, 66
Bradley, Luke	61	Fotinos, Kathryn	57, 58
Braeckman, Rene	63	Fox, Nathan	58
Brams, Matt	66	Frank, Barbara	19, 48, 49
Brikell, Isabell	67	Friedman, Lauren	58
Brown, Thomas	24, 42, 63	Fried, Ronna	43, 56, 57, 63, 65
Buchanan, Tom	60	Froehlich, Tanya	24
Burton, Christie	61	Fuemmeler, Bernard	61
Busch, Betsy	23	Gabrieli, John	20, 48, 62
Calhoun, Sue	55	Gaillard, Schuyler	62
Cameron, Cathy	58	Galdo, Maribel	57, 63
Carrellas, Nicholas	56	Gerhardt, Greg	61
Ceranoglu, Tolga Atilla	63, 66	Gibbons, Robert	67
Ceresoli-Borroni, Gianpiera	64	Giedd, Jay	21, 44, 48
Chan, James	56	Glaser, Paul	40, 61

AUTHOR INDEX

Glatt, Stephen	62	Konofal, Eric	67
Gnagy, Elizabeth	58	Kooij, J.J. Sandra	24, 50
Goldman, Robert	67	Korgaonkar, Mayuresh	62
Goldstein, Sam	24	Krone, Beth	62
Gomeni, Roberto	65	Kuja-Halkola, Ralf	65
Goodman, David	24	Larsson, Henrik	65, 67
Grace, Anthony	12, 33	Leahy, Meghan	60
Griffiths, Kristi	62	Lejuez, Carl	59
Grizenko, Natalie	63	Leon, Terry L.	56
Grossman, Rebecca	66	Levin, Frances	23, 37
Guenther, Sven	63	Lewis, Kari	55
Hall, Anna	56	Liao, Duanping	60
Hammerness, Paul	67	Lindstrom, Rachel	64
Handal, Nelson	67	Liranso, Tesfaye	64
Harty, Seth	64	Littrell, Meagan	61
Hegarty, Jani	55	Loebel, Antony	65, 67
Heiligenstein, John	24	Loo, Sandra	65
Hernandez, Mariely	9	Lopez, Victor	62
Hess, Jonathon	62	Lubaczewski, Shannon	55
Hopkins, Seth	65, 67	Lunsford-Avery, Jessica	60
Hoskova, Barbora	57, 63	Lusby, Cara	60
Hsu, Jay	67	MacDonald, J.	61
Huettl, Peter	61	Mahone, Mark	57
Hung, Yuwen	62	Majors, Alesha	61
Hur, Kwan	67	Manor, Iris	24, 50
Iaccarino, Mary Alexis	57	Marraffino, Andrea	64
Inclendon, Beverly	60, 61, 65, 67	Marshall, Christian	61
Isquith, Peter	65	Martelon, Mary Kate	8, 59
Ivanov, Iliyan	57	Masson, Neil	66
Jacobs, Lisa	9	Mattingly, Greg	24, 55
Jacobson, Lisa	57, 60	McBurnett, Keith	24, 58
Jain, Rakesh	55	McClermon, F. Joseph	59
Jangmo, Andreas	40, 65	McGough, James	65
Jensen, Peter S.	60	McKone, Kirsten	58
Joobar, Ridha	63	McMahen, Russ	66
Joseph, Heather	64	Merico, Daniel	61
Joshi, Gagan	57, 59, 63	Mickle, Travis	63
Kalb, Luke	60	Miller, Natalie	9, 58
Katzman, Martin	57, 58	Mills, Sara	55
Kelberman, Caroline	56, 62	Mitchell, John	59, 60
Kennedy, Traci	9, 58	Molina, Brooke	43, 58, 64
Khachatryan, Alexandra	60	Mukherjee, Dahlia	60
Kim, Kristen	57	Mukherjee, Prerona	9
Kipp, Heidi	64	Mulligan, louletta	67
Koblan, Kenneth	65, 67	Nadeau, Kathleen	23, 42
Kohn, Michael	62	Natsheh, Joman	40, 62
Kollins, Scott	23, 41, 59, 60, 61, 64, 67	Newcorn, Jeffrey	23, 24, 47, 57, 62, 67
		Newman, Bridget	64

AUTHOR INDEX

Nierenberg, Andrew	24, 51	Scherer, Steven	61
Norman, Luke	9	Schmith, Virginia	67
Nullmeier, Rick	61	Schulz, Kurt	40, 62
Nutt, Michael	63	Sergeant, Joseph	7, 35, 38
O'Brien, Quentin	55	Shiflett, Michael	62
Otcheretko, Victor	63	Shimko, Eitan	60
Oyedele, Natasha	66	Sikes, Carolyn	66
Pacelli, Sydney	62	Silva, Raul	66
Palumbo, Donna	55	Silverstein, Michael	56
Pardo, Antonio	64	Siner, David	66
Parvaz, Muhammad	57	Sleeper-Triplett, Jodi	52
Patak, Jameson	9, 62	Sloan, Jessica Solis	60
Paterson, Andrew	61	Smith, Adam	63
Pearl, Amanda	60	Smith, Katherine	55
Pedersen, Sarah	58	Solanto, Mary	24
Pedraza, Juan	62	Soltanifar, Mohsen	61
Pelham, William	58	Sonuga-Barke, Edmund	17, 47, 50
Pennington, Bruce	61	Soutullo, César	50
Perlis, Roy	56	Spencer, Andrea	66
Pfiffner, Linda	58	Spencer, Thomas	8, 24, 56, 57
Pikalov, Andrei	67	Stacey, Engster	64
Pille, Rebecca O.	55	Stålhandske, Amanda	65
Pliszka, Steven	23, 49, 67	Stark, Jeffrey	66
Pomerleau, Francois	61	Stein, Jeffrey	49
Pope, Amanda	56	Stein, Mark	23, 37, 38, 42
Posner, Jonathan	51	Sternat, Tia	57, 58
Pritchard, Alison	60	Stevens, Howard	66
Pulli, Alexa	56, 57, 59	Stolper, Robert	60
Quinn, Patrick	67	Storch, Barbara	56
Ramaker, Sara	55	Straughn, Arthur	66
Ramsay, J. Russell	24, 43	Stringaris, Argyris	51
Rhodewalt, Lauren	66	Strug, Lisa	61
Robb, Adelaide	44	Sturm, Alexandra	65
Robbins, Trevor	11, 33	Surman, Craig	24, 63, 66
Robertson, Brigitte	60, 63, 64	Sweitzer, Maggie	60
Rohde, Luis	23	Sykes, Carolyn R.	64
Rostain, Anthony	23, 51	Taylor, Lea	55, 56, 57
Roth, Robert	65	Teuscher, Nathan	66
Roupe, Kathryn	63	Thakkar, Vatsal	23
Rubin, Jonathan	66	Thapar, Anita	16, 47
Saad, Jacqueline	40, 62	Tolbert, Sierra	61
Saba, Victoria	61	Tsai, Joyce	67
Saito, Takuya	50	Tuttle, Lisa	52
Sallee, F. Randy	60, 61, 65, 67	Uchida, Mai	56, 59, 62, 66
Saunders, Erika	60	Vaudreuil, Carrie	66
Schachar, Russell	23, 39, 41, 61	Villodas, Miguel	58
Schaffer, Shane	66	Waite, Roberta	24, 60
Schechter, Julia	60, 61	Walther, Christine	58

AUTHOR INDEX

Waschbusch, Daniel	55, 60	Woodworth, Hilary	56
Wasserstein, Jeanette	42	Woodworth, K. Yvonne	8, 56, 57, 59
Waxmonsky, James	55, 60	Wozniak, Janet	44, 57, 59
Weiss, Margaret	24, 50	Xiao, B.	61
Wigal, Sharon	55, 67	Yan, Brian	64
Wigal, Tim	67	Yu, Ming	64
Wiggs, Kelsey	40, 67	Yule, Amy	39, 59, 63, 66
Wilens, Timothy	13, 37, 44, 59, 60, 61, 67	Zabel, T. Andrew	60
Willcutt, Erik	61	Zafonte, Ross	57
Williams, Leanne	62	Zamora, Cynthia	63
Wise, Barbara	59	Zarrei, Mehdi	61
Wolenski, Rebecca	59	Zhang-James, Yanli	62

NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Become an APSARD Member Today!

Visit www.APSARD.org for details!

